Sponsored
released by
Evonik
07.20.23
Cytotoxics And High Potency Manufacturing
Breaking News
- All
- APIs
- Aseptic Processing
- cGMP Manufacture
- Cleaning Validation
- Clinical Trial Materials
- Cytotoxics and High Potency Manufacturing
- Excipients
- Extractables and Leachables
- Facilities
- Fill/Finish
- Lyophilization
- Parenterals
- Process Development
- Process Validation
- Risk Management
- Scale-up/Technology Transfer
- Solid Dosage/Creams/Ointments
-
Capsules | Cytotoxics and High Potency Manufacturing | Solid Dosage/Creams/Ointments | Solid Dosage/Semi-solids
Multi-particulate Formulations – Tablets or Capsules?
Multiple-unit dosage forms are gaining significant popularity among drug developers due to their benefits.Subhashis Chakraborty and Ananya Sen, ACG 03.11.24
-
Cytotoxics and High Potency Manufacturing | Drug Development
Trends in the Development of ADCs
Targeting tumor heterogeneity with antibody-drug conjugates and novel payloads.Louise Duffy, Chief Technical Officer, Abzena 02.01.24
-
Cytotoxics and High Potency Manufacturing | Drug Development | Process Development
HPAPI Trends: Drug Synthesis in Early Development
Addressing the challenge of new clinical targets and highly potent compounds.Rob Abbenhuis, Chemistry Division Manager, Ardena 02.01.24
-
cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Drug Development | Fill/Finish | Information Technology
Calling All Laureates in Oncology Drug Manufacturing
Leveraging technology to reduce development timelines while maintaining safety will be key to delivering critical oncology products.Rebecca Coutts, General Manager, PCI Pharma Services 02.01.24
-
APIs | Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing
Olon Group to Add New High Potency API Suite in Ohio
Expands its capabilities to serve clients developing innovative therapies for cancer, rare diseases and other challenging therapeutic areas.01.29.24
-
APIs | Cytotoxics and High Potency Manufacturing
Trends in the Development of ADCs
Targeting tumor heterogeneity with antibody-drug conjugates and novel payloads.Louise Duffy, Chief Technical Officer, Abzena 01.25.24
-
APIs | Cytotoxics and High Potency Manufacturing
API Market Trends
Companies are looking to diversify their API suppliers and manufacturers to different locations instead of outsourcing it to just one manufacturer.Online Exclusives Grand View Research 01.25.24
-
Breaking News | Cytotoxics and High Potency Manufacturing | Drug Development | Drug Discovery | Industry News
Experic Installs New Capsule Filling Machine at New Jersey Facility
Provides enhanced protection of employees and the environment from highly potent pharmaceutical products.12.07.23
-
Cytotoxics and High Potency Manufacturing
Developing HPAPIs: Leveraging Classification Systems to Mitigate Risk
Exploring the importance of robust classification systems to accurately characterize and classify HPAPIs for safe handling.Catherine Wilkes, Executive Director of Environmental, Health & Safety, Quotient Sciences 11.14.23
-
Cytotoxics and High Potency Manufacturing
ABCs of ADCs: A Brief Primer
Reviewing some pros and cons that exist within the outsourcing realm for antibody drug conjugates.Ben Locwin , Contributing Editor 11.14.23
-
cGMP Manufacture | Cytotoxics and High Potency Manufacturing
The Evolution of HPAPI Manufacturing for CDMOs
The demand for highly potent APIs has been steadily increasing, driven by the development of targeted therapies in oncology and other disease areas.Adam Kujath, EVP and Site Head, Germantown, Sterling Pharma Solutions 10.12.23
-
cGMP Manufacture | Cytotoxics and High Potency Manufacturing
"3 Key Trends" with Srinivasan Shanmugam
Adare Pharma Solutions’ Senior Director of Pharmaceutical Sciences, Business Support, and New Technologies offers his thought leadership.Online Exclusives Contract Pharma 09.28.23
-
Cytotoxics and High Potency Manufacturing | Facilities
HPAPI Manufacturing Trends
Oncology drugs, advancements in manufacturing technology, and a rise in capacity to meet greater demand drive market growth.Tim Wright, Editor, Contract Pharma 09.13.23
-
Cytotoxics and High Potency Manufacturing | Drug Development
"3 Key Trends" with Louise Duffy
Abzena’s Chief Technical Officer offers her thought leadership.Online Exclusives Contract Pharma 08.04.23
-
Analytical Services | APIs | Bioanalytical Services | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Drug Development | Laboratory Testing
Talking Toxicology for Safer HPAPIs
Toxicological evaluation is important at every stage of HPAPI development and manufacturing—CDMOs help ensure new treatments are brought to market safely.
-
Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
WuXi STA Debuts First HP Sterile Injectable Mfg. Line at Wuxi Site
Annual capacity of 12 million units enhances manufacturing capabilities and capacity for injectable dosage forms.07.18.23
-
Breaking News | Clinical Trial Materials | Cytotoxics and High Potency Manufacturing | Drug Development | Industry News
NorthStar Medical Radioisotopes Executes Supply Agreement with Bayer
NorthStar’s non-carrier added Ac-225 to be used in Bayer’s radiopharmaceutical programs.07.18.23
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Aenova Opens New Building for Highly Potent Drugs
Makes total investment of around €25 million at the Regensburg site to increase development and production capacities.06.23.23
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Drug Development | Drug Discovery | Facilities | Industry News
OLON Enters ADC Market
Invests €22 million in a new facility dedicated to ultra-potent compounds.05.30.23
-
APIs | Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Drug Development | Industry News
AmbioPharm Expands South Carolina Headquarters
Includes increasing synthesis capacity and supporting growth in late phase and commercial production.05.18.23
